Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050-4. doi: 10.1073/pnas.0801227105. Epub 2008 Jun 9.

2.

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D; Alzheimer's Disease Neuroimaging Initiative, Morris JC, Fagan AM, Holtzman DM, Goate AM.

PLoS Genet. 2010 Sep 16;6(9):e1001101. doi: 10.1371/journal.pgen.1001101.

3.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
4.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

5.

High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease.

Compta Y, Ezquerra M, Muñoz E, Tolosa E, Valldeoriola F, Rios J, Cámara A, Fernández M, Buongiorno MT, Marti MJ.

Neurosci Lett. 2011 Jan 7;487(2):169-73. doi: 10.1016/j.neulet.2010.10.015. Epub 2010 Oct 15.

PMID:
20951764
6.

The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA; Alzheimer's Disease Neuroimaging Initiative; Genetic and Environmental Risk for Alzheimer's Disease Consortium GERAD, Fagan AM, Holtzman D, Morris JC, Goate AM, Cruchaga C.

PLoS Genet. 2013;9(8):e1003685. doi: 10.1371/journal.pgen.1003685. Epub 2013 Aug 22.

7.

Genetic analysis of genes involved in amyloid-β degradation and clearance in Alzheimer's disease.

Natunen T, Helisalmi S, Vepsäläinen S, Sarajärvi T, Antikainen L, Mäkinen P, Herukka SK, Koivisto AM, Haapasalo A, Soininen H, Hiltunen M.

J Alzheimers Dis. 2012;28(3):553-9. doi: 10.3233/JAD-2011-111109.

PMID:
22027013
8.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
9.

Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease.

Laws SM, Friedrich P, Diehl-Schmid J, Müller J, Eisele T, Bäuml J, Förstl H, Kurz A, Riemenschneider M.

Mol Psychiatry. 2007 May;12(5):510-7. Epub 2006 Dec 19.

PMID:
17179995
10.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
11.

Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM; Alzheimer's Disease Neuroimaging Initiative, Goate AM.

J Alzheimers Dis. 2010;21(3):833-42. doi: 10.3233/JAD-2010-091711.

12.

GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan AM, Holtzman DM, Morris JC; GERAD Consortium; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Goate AM.

Neuron. 2013 Apr 24;78(2):256-68. doi: 10.1016/j.neuron.2013.02.026. Epub 2013 Apr 4.

13.

Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism.

Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, Gatz M, Wilcock GK, Love S, Pedersen NL, Brookes AJ, Blennow K, Kehoe PG, Prince JA.

Hum Mutat. 2004 Apr;23(4):358-67.

PMID:
15024730
14.

The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.

Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L.

Arch Gen Psychiatry. 2011 Feb;68(2):207-13. doi: 10.1001/archgenpsychiatry.2010.196.

PMID:
21300948
15.

PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.

Balasa M, Vidal-Piñeiro D, Lladó A, Antonell A, Bosch B, Castellanos F, Bargalló N, Bartres-Faz D, Molinuevo JL, Sánchez-Valle R.

J Alzheimers Dis. 2012;30(3):605-16. doi: 10.3233/JAD-2012-111949.

PMID:
22426017
16.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
17.
18.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
19.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
20.

Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. doi: 10.1007/s00406-008-0838-3. Epub 2008 Sep 19.

PMID:
18806919
Items per page

Supplemental Content

Write to the Help Desk